Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-02-15
2002-07-16
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S364000, C514S415000, C514S224800
Reexamination Certificate
active
06420405
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity or a salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity, and to a method of its use.
BACKGROUND OF THE INVENTION
Diuretic drugs, due to their having mild hypotensive effects, have long been clinically used as antihypertensive agents. However, as undesirable side effects caused by the use for a long time, influences on metabolism, for example, hypokalemia, hyperuricemia, hyperlipemia and diabetes melitus, have been taken up. While calcium antagonists have been used as therapeutic agents of circulatory diseases such as hypertension, cardiac diseases, cerebral apoplexy, nephritis and arteriosclerosis, it has also been known that they tend to cause such undesirable side effects as tachycardia, hypotension, erythroprosopalgia and encephalagia, which are considered to be due to their abrupt vasodilative action.
On the other hand, it is disclosed in EP-0425921, EP-0459136 and EP-0520423 that benzimidazole derivatives have an angiotensin II antagonistic activities and are useful for the therapy of circulatory diseases including hypertension, cardiac diseases (cardiac insufficiency, myocardial infarction, etc.), cerebral apoplexy, nephritis and arteriosclerosis. The mechanism of the action is considered that the benzimidazole derivatives inhibit the binding of angiotensin II having a strong vasoconstrictive action to an angiotensin II acceptor. And, while, in JPA, H3(1991)-27362 and JPA H5(1993)-132467, it is disclosed that an imidazole derivative having angiotensin II antagonistic action is administered together with a diuretic agent or a calcium antagonistic agent.
OBJECT OF THE INVENTION
The invention is intended, by combination of a compound having angiotensin II antagonistic action or a salt thereof with a compound having diuretic action or a compound having calcium antagonistic activity, to perform especially remarkable effects, to reduce undesirable side effects and to cover up defects observed in administration of a medicine consisting of a single component.
SUMMARY OF THE INVENTION
Circumstances being such as above, the present inventors have made extensive and intensive studies on the effects of co-use of a benzimidazole derivative having angiotensin antagonistic activity with a compound having diuretic activity or a compound having calcium antagonistic activity, and, as a result, they have found that the co-use performs especially remarkable effects which were not observed in the administration of the respective compounds singly, thus accomplishing the present invention.
More specifically, the present invention relates to
(1) a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula (I):
wherein R
1
is H or an optionally substituted hydrocarbon residue; R
2
is an optionally esterified carboxyl group; R
3
is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R
2
; and Y is a bond, —O—, —S(O)m- (wherein m is 0, 1 or 2) or —N(R
4
)— (wherein R
4
is H or an optionally substituted alkyl group) or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity, and (2) a method for the prophylaxis or treatment of angiotensin II-mediated diseases in a mammal which comprises administering an effective amount of a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof in combination with an effective amount of a compound having diuretic activity or a compound having calcium antagonistic activity.
REFERENCES:
patent: 4139633 (1979-02-01), Brunner et al.
patent: 4178374 (1979-12-01), Sweet
patent: 4547498 (1985-10-01), Blume et al.
patent: 4855289 (1989-08-01), Wester et al.
patent: 4880804 (1989-11-01), Carini et al.
patent: 4895846 (1990-01-01), Poindexter et al.
patent: 5128356 (1992-07-01), Naka et al.
patent: 5162326 (1992-11-01), Naka et al.
patent: 5164509 (1992-11-01), Atwal
patent: 5183899 (1993-02-01), Naka et al.
patent: 5187159 (1993-02-01), Greenlee et al.
patent: 5250554 (1993-10-01), Naka et al.
patent: 5284661 (1994-02-01), Naka et al.
patent: 5656650 (1997-08-01), Weinstock
patent: 5736554 (1998-04-01), Spada et al.
patent: 6245787 (2001-06-01), Cropp et al.
patent: 3633114 (1988-03-01), None
patent: 0154009 (1985-09-01), None
patent: 0279750 (1988-08-01), None
patent: 0312157 (1989-04-01), None
patent: 0400835 (1990-05-01), None
patent: 0430300 (1991-06-01), None
patent: 0434038 (1991-06-01), None
patent: 0445811 (1991-09-01), None
patent: 0459136 (1991-12-01), None
patent: 0483683 (1992-05-01), None
patent: 0490587 (1992-06-01), None
patent: 0501892 (1992-09-01), None
patent: 0518033 (1992-12-01), None
patent: 0520423 (1992-12-01), None
patent: 0532410 (1993-03-01), None
patent: 0537937 (1993-04-01), None
patent: 2419728 (1979-10-01), None
patent: 2270841 (1994-03-01), None
patent: 9100277 (1991-01-01), None
patent: 9100281 (1991-01-01), None
patent: 9210097 (1992-06-01), None
patent: 9317685 (1993-09-01), None
patent: 9409778 (1994-05-01), None
“Low Doses of Hydrochlorothiazide in Hypertension Antihypertensive and Metabolic Effects”, G. Berglund, et al.,Europ. J. Clin. Pharmacol.,vol. 10, pp. 177-182 (1976).
“Antihypertensive Effect of Various Doses of Hydrochlorothiazide and its Relation to the Plasma Level of the Drug”, B. Beerman, et al.,Europ. J. Clin. Pharmacol.,vol. 13, pp. 195-201 (1978).
“Effects if a nonpeptide angiotensin if receptor antagonist (CV-11974) on [Ca2+]; and cell motion in cultured ventricular myocytes”, Kinugawa, et al.,Europ. J. Pharmacol.,vol. 235, pp. 313-316 (1993).
“Antihypertensive Effects of Highly Potent and Long-Acting Angiotensin II Subtype-1 Receptor Antagonist, (±)-1-(Cyclohexyloxycarbonyloxy) 2-Ethoxy-1-[[2'-(1H-Tetrazol-5-y)Biphenyl-4-yl]Methyl]-1H-Benzimidazole-7-Carboxylate(TCV-116), in Various Hypertensive Rats”, Inada et al.,J. Pharmacol. and Experim. Therapeutics.,vol. 268, No. 3, pp. 1540-1547 (1994).
“Chronic Angiotensin II (All) Receptor Blockade Lowers Arterial Pressure (AP) and Glomerular Capillary Pressure (PGC) in Diabetic Rats” Anderson et al.,American J. of Hypertension,vol. 4, 11A-12A (1991).
“Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effect on a renin-induced deficit of a passive avoidance response in rats” Denoble et al.Brain Research,vol. 561, pp. 230-235 (1991).
“Quantitative Autoradiography Reveals Different Angiotensin II Receptor Subtypes in Selected Rat Brain Nuclei” Tsutsumi et al.J. of Neurochem.,vol. 56, No. 1, pp. 348-351 (1991).
“TCV-116 , a Novel Angiotensin II Receptor Antagonist, Prevents Intimal Thickening and Impairment of Vascular Function after Carotoid Injury in Rats” Kawamura et al.,J. Pharmacol. and Experim. Therapeutics,vol. 266, No. 3, pp. 1664-1669 (1993).
“Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone” Wada et al.,Eur. J. Pharmacol.,vol. 253, pp. 27-34 (1994).
“Involvement of the Renin-Angiotensin System in Ischemic Damage and Reperfusion Arrhythmias in the Isolated Perused Rat Heart”, Fleetwood et al.,J. Cardiovas. Pharmacol.,vol. 17, pp. 351-356 (1991).
Inada Yoshiyuki
Kubo Keiji
Foley & Lardner
Lambkin Deborah C.
Takeda Chemical Industries Ltd.
LandOfFree
Pharmaceutical composition for angiotensin II-mediated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for angiotensin II-mediated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for angiotensin II-mediated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2905160